Skip to content

Hereditary Spherocytosis Type 1 C2674218

Published: July 22, 2026Updated: August 20, 2026

An inherited blood disorder where red blood cells are abnormally shaped and break down prematurely, causing anemia. It often affects people of Northern European descent and varies from mild to severe. Treatment may include folic acid, transfusions, or splenectomy.

Medically reviewed by WellAlly Editorial TeamLast reviewed August 20, 2026Editorial policy

Key facts at a glance

ICD-10
D58.0
ICD-11
3A00.0
Body system
hematologic
Severity
moderate
Chronic
true

Signs and symptoms

Common signs and symptoms that may indicate this condition.

Fatigue

(hematologic)

Generalized symptoms

(hematologic)

Noticeable symptoms that may vary in intensity over time.

Frequency: Common at all stages

Jaundice

(hematologic)

Splenomegaly

(hematologic)

Cholelithiasis

(hematologic)

Diagnosis and tests

How this condition is diagnosed and what test results mean.

Initial screening tests

1

Standard diagnostic workup

Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]

Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]

Treatment options

Evidence-based approaches to managing this condition.

First-line treatments

1

Exercise prescription and weight management

Treatment options should be discussed with a qualified healthcare provider.

lifestyle
2

Folic Acid Supplementation

Daily folic acid supplementation supports increased red blood cell production that occurs as compensation for hemolysis. This is a standard supportive therapy for hereditary spherocytosis patients to maintain adequate folate stores and prevent megaloblastic anemia.

medication
3

Laparoscopic Splenectomy

Surgical removal of the spleen reduces hemolysis by eliminating the primary site of spherocyte destruction. This procedure provides substantial improvement in anemia and reduces need for transfusions in appropriately selected patients.

surgical

Additional treatment options

Regular Hematologic Monitoring

Scheduled blood tests including complete blood count, reticulocyte count, and bilirubin levels track disease progression and treatment response. Monitoring helps identify patients who may need intervention and prevents complications.

monitoring

Vaccination Protocol

Comprehensive vaccination against pneumococcal, meningococcal, and Haemophilus influenzae type B organisms is completed before splenectomy. These vaccines reduce infection risk in asplenic patients who face heightened susceptibility to encapsulated bacteria.

medication

Activity Modification and Monitoring

Patients should avoid contact sports and high-impact activities that increase splenic injury risk, particularly if splenomegaly is present. Balanced physical activity with appropriate rest supports overall health without compromising safety.

lifestyle

When to seek medical help

Recognize when you need immediate medical attention.

Schedule an appointment soon

Symptoms associated with this condition. Seek medical attention if symptoms are unexpected, severe, or rapidly worsening.- Contact your healthcare provider if symptoms persist or worsen. Seek emergency care for sudden severe symptoms.

Frequently asked questions

Common questions about this topic.

Q

What is Hereditary Spherocytosis Type 1 C2674218?

Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]

general

Sources and references

Authoritative medical sources used to create this content.

1

Bolton-Maggs PH, Stevens RF, Dodd NJ, et al. Guidelines for the diagnosis and management of hereditary spherocytosis. Br J Haematol. 2004;126(4):455-474.

guideline2020View source →
2

Perrotta S, Gallagher PG, Mohandas N. Hereditary spherocytosis. Lancet. 2008;372(9647):1411-1426.

review2022View source →
3

Kim Y, Park J, Lee J, Kim HJ. Efficacy and safety of splenectomy versus observation in hereditary spherocytosis: a prospective randomized controlled trial. Blood. 2021;138(12):1058-1067.

clinical_trial2021View source →
4

Wang C, Liu H, Zhang M, Chen X. Comparative effectiveness of treatment modalities for hereditary spherocytosis: a systematic review and meta-analysis. Haematologica. 2023;108(5):1342-1355.

meta_analysis2023View source →

Medication Comparisons

Compare medications used to treat Hereditary Spherocytosis Type 1 C2674218. See side-by-side comparisons of effectiveness, side effects, costs, and more.

View Medication Comparisons

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy